MAURICIO DENER CORDEIRO
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/55 - Laboratório de Urologia, Hospital das Clínicas, Faculdade de Medicina
LIM/55 - Laboratório de Urologia, Hospital das Clínicas, Faculdade de Medicina
17 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 17
- Correlation of a microRNA expression profile and the prognosis of penile cancer: A prospective study using microarray data analysis(2018) FURUYA, Tatiane K.; MURTA, Claudio B.; PONTES JR., Jose; UNO, Miyuki; CARRASCO, Alexis; SICHERO, Laura C.; VILLA, Luisa L.; COELHO, Rafael F.; GUGLIELMETTI, Giuliano B.; CORDEIRO, Mauricio D.; LEITE, Katia R.; SROUGI, Miguel; CHAMMAS, Roger; NAHAS, William C.
- Tumor mutational burden (TMB) and BCG responsiveness in high-risk non-muscle invasive bladder cancer (NMIBC).(2019) BASTOS, Diogo Assed; LIMA, Mariana; MATTEDI, Romulo Loss; SANTOS, Filipe Ferreira dos; BUZATTO, Vanessa; BARREIRO, Rodrigo; RIBEIRO-FILHO, Leopoldo; CORDEIRO, Mauricio; AMANO, Mariane; SOUZA, Jussara Michaloski; BETTONI, Fabiana; GALANTE, Pedro Alexandre Favoretto; DZIK, Carlos; NAHAS, William Carlos; CAMARGO, Anamaria Aranha
- Renal cell carcinoma with perirenal fat invasion: Is partial nephrectomy as good as radical surgery?(2017) CORDEIRO, Mauricio; BASTOS, Diogo Assed; GALLUCCI, Fabio Pescarmona; BARBOSA, Joao Arthur Brunhara; ILARIO, Eder Nisi; CARVALHO, Paulo Afonso De; NONEMACHER, Henrique T. S.; ALBUQUERQUE, George Lins; MATTEDI, Romulo Loss; CARVALHO, Arnaldo Fazoli; NAHAS, William Carlos
conferenceObject Randomized phase II trial of neoadjuvant androgen deprivation therapy plus abiraterone and apalutamide for patients with high-risk localized prostate cancer: Pathologic response and PSMA imaging correlates.(2022) BASTOS, Diogo Assed; COELHO, Rafael; CARDILI, Leonardo; GALIZA, Felipe; ILARIO, Eder Nisi; VIANA, Ublio; MURTA, Claudio Bovolenta; GUGLIELMETTI, Giuliano; CORDEIRO, Mauricio; PONTES JR., Jose; MUNIZ, David Queiroz Borges; SILVA, Jamile Almeida; MOTA, Jose Mauricio; FREITAS, Guilherme Fialho De; LEITE, Katia Ramos Moreira; BUCHPIGUEL, Carlos Alberto; NAHAS, William Carlos- Extended versus limited pelvic lymphadenectomy during radical prostatectomy for intermediate- and high-risk prostate cancer: Early outcomes from a randomized controlled phase III study.(2017) LESTINGI, Jean Felipe Prodocimo; GUGLIELMETTI, Giuliano; PONTES JR., Jose; MITRE, Anuar Ibrahim; SARKIS, Alvaro; BASTOS, Diogo Assed; RIECHELMANN, Rachel; MATTEDI, Romulo Loss; CORDEIRO, Mauricio; COELHO, Rafael; SROUGI, Miguel; NAHAS, William Carlos
- Tumor mutational burden (TMB), intratumoral genetic heterogeneity (ITGH) and BCG responsiveness in high-risk non-muscle invasive bladder cancer (NMIBC).(2018) BASTOS, Diogo Assed; LIMA, Mariana; MATTEDI, Romulo Loss; DZIK, Carlos; RIBEIRO-FILHO, Leopoldo; CORDEIRO, Mauricio; NAHAS, William Carlos; SOUZA, Jussara Michaloski; AMANO, Mariane; BETTONI, Fabiana; BUZATTO, Vanessa; SANTOS, Filipe Ferreira dos; BARREIRO, Rodrigo; GALANTE, Pedro Alexandre Favoretto; CAMARGO, Anamaria Aranha
- Genomic Biomarkers and Underlying Mechanism of Benefit from BCG Immunotherapy in Non-Muscle Invasive Bladder Cancer(2020) BASTOS, Diogo A.; MATTEDI, Romulo L.; BARREIRO, Rodrigo; SANTOS, Filipe F. dos; BUZATTO, Vanessa; MASOTTI, Cibele; SOUZA, Jussara M.; LIMA, Mariana Z. T. de; FRIGUGLIETTI, Giulia W.; DZIK, Carlos; JARDIM, Denis L. F.; COELHO, Rafael; RIBEIRO FILHO, Leopoldo A.; CORDEIRO, Mauricio D.; NAHAS, William C.; MELLO, Evandro S. de; CHAMMAS, Roger; REIS, Luiz Fernando L.; BETTONI, Fabiana; GALANTE, Pedro A. F.; CAMARGO, Anamaria A.BACKGROUND: Optimal therapy for high-risk non-muscle invasive bladder cancer (NMIBC) includes intravesical instillation of Bacillus Calmette-Guerin (BCG). However, about 25-45% of patients do not benefit from BCG immunotherapy, and there is no biomarker to guide therapy. Also, many questions regarding BCG mechanisms of action remain unanswered. OBJECTIVE: To identify genomic biomarkers and characterize the underlying mechanism of benefit from BCG in NMIBC. PATIENTS AND METHODS: Pre-treatment archival index-tumors of 35 patients with NMIBC treated with BCG were analyzed by whole-exome sequencing (WES). Tumor mutation burden (TMB) and neoantigen load (NAL) were correlated with BCG response rate (RR) and recurrence-free survival (RFS). The presence of deleterious mutations in DNA damage response (DDR) genes was also compared between BCG-responsive (BCG-R, N= 17) and unresponsive (BCG-UR, N= 18) subgroups. RESULTS: TMB and NAL were higher in BCG-R compared to BCG-UR patients (median TMB 4.9 vs. 2.8 mutations/Mb, P = 0.017 and median NAL 100 vs. 65 neoantigens, P = 0.032). Improved RR and RFS were observed in patients with high vs. low TMB (RR 71% vs. 28%, P = 0.011 and mRFS 38.0 vs. 15.0 months, P = 0.009) and with high vs. low NAL (RR 71% vs. 28%, P = 0.011 and mRFS 36.0 vs. 18.5 months, P = 0.016). The presence of deleterious mutations in DDR genes was associated with improved RFS (mRFS 35.5 vs. 11.0 months, P = 0.017). CONCLUSIONS: In our cohort, improved outcomes after BCG immunotherapy were observed in patients with high TMB, high NAL and deleterious mutations in DDR genes. BCG may induce tumor-specific immune response by enhancing the recognition of neoantigens.
- MCT1 expression is independently related to shorter cancer-specific survival in clear cell renal cell carcinoma(2021) CARVALHO, Paulo Afonso de; BONATELLI, Murilo; CORDEIRO, Mauricio Dener; COELHO, Rafael Ferreira; REIS, Sabrina; SROUGI, Miguel; NAHAS, Willian Carlos; PINHEIRO, Celine; LEITE, Katia Ramos MoreiraClear cell renal cell carcinoma (ccRCC) has been considered a metabolic disease, with loss of von Hippel-Lindau (VHL) gene and consequent overexpression of hypoxia-inducible factor 1 alpha (HIF-1a), which is central for tumor development and progression. Among other effects, HIF-1a is involved in the metabolic reprogramming of cancer cells towards the Warburg effect involved in tumor cell proliferation, migration and survival. In this context, several proteins are expressed by cancer cells, including glucose and lactate transporters as well as different pH regulators. Among them, monocarboxylate transporters (MCTs) can be highlighted. Our aim is to comprehensively analyze the immunoexpression of MCT1, MCT2, MCT4, CD147, CD44, HIF-1 alpha, GLUT1 and CAIX in ccRCC surgical specimens correlating with classical prognostic factors and survival of patients with long follow-up. Surgical specimens from 207 patients with ccRCC who underwent radical or partial nephrectomy were used to build a tissue microarray. Immunostaining was categorized into absent/weak or moderate/strong and related to all classic ccRCC prognostic parameters. Kaplan-Meier curves were generated to assess overall and cancer-specific survival, and multivariate analysis was performed to identify independent prognostic factors of survival. Multivariate analysis showed that MCT1 together with tumor size and TNM staging, were independently related to cancerspecific survival. MCT1, CD147, CD44 and GLUT1 expression were significantly associated with poor prognostic factors. We show that MCT1 is an independent prognostic factor for cancer-specific survival in ccRCC justifying the use of new target therapies already being tested in clinical trials.
- Oncological outcomes of positive surgical margins in partial nephrectomy for renal cell carcinoma.(2017) NONEMACHER, Henrique T. S.; CORDEIRO, Mauricio; ALBUQUERQUE, George Lins De; GALUCCI, Fabio; CARVALHO, Paulo Afonso de; BORGES, Leonardo; GUGLIELMETTI, Giuliano Betuni; BASTOS, Diogo Assed; COELHO, Rafael; SARKIS, Alvaro; DZIK, Carlos; NAHAS, William Carlos
- Tumor contact length used as a biomarker to predict extracapsular extension, lymph node involvement, and biochemical recurrence.(2019) VIANA, Publio; RODRIGUES, Thiana; MOTA, Davi Alves Martins; GUGLIELMETTI, Giuliano; BASTOS, Diogo Assed; FAZOLI, Arnaldo; NAHAS, William Carlos; COELHO, Rafael; CORDEIRO, Mauricio; HORVAT, Natally